Gland Pharma's generic version of GIAPREZA, used to raise blood pressure in septic shock, has secured exclusive 180-day US market rights. With $58 million in recent sales, Gland Pharma continues its rapid global growth, offering a broad injectable portfolio across 60 countries.

• First-to-file generic with 180 days of exclusivity in the US.
• $58 million US sales in 12 months ending March 2025.
• Operates in 60 countries with diverse injectable products.